Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy.
about
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant womenGlobal report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.A Systematic Review of Interventions to Reduce Maternal Mortality among HIV-Infected Pregnant and Postpartum WomenAssociation between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.Pregnant women's access to PMTCT and ART services in South Africa and implications for universal antiretroviral treatment.Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trialPregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conceptionMaternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in BotswanaHighly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.Mitochondrial toxicity in human pregnancy: an update on clinical and experimental approaches in the last 10 years.Antiretroviral regimens in pregnancy and breast-feeding in Botswana.An important clinical lesson from a patient infected with HIV with diabetic nephropathy and retinopathy.Efavirenz use during pregnancy and for women of child-bearing potentialSafety and tolerability of antiretrovirals during pregnancy.Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational studyRisk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretroviralsThe Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations.Prevention of mother-to-child transmission of HIV: treatment options.Mitochondrial disease in the offspring as a result of antiretroviral therapy.Treating HIV during pregnancy: an update on safety issues.Duration of cART Before Delivery and Low Infant Birthweight Among HIV-Infected Women in Lusaka, Zambia.Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy.Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Treatment interruption after pregnancy: effects on disease progression and laboratory findingsIncreased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.Managing mother-to-child transmission of HIV infection in developed-country settings.Ten years of experience in the prevention of mother-to-child human immunodeficiency virus transmission in a university teaching hospital.Antiretroviral use during pregnancy for treatment or prophylaxis.HIV protease inhibitors in pregnancy : pharmacology and clinical use.Antiretroviral therapy and preterm birth in HIV-infected women.Tolerance of the newborn to antiretroviral drug exposure in utero.
P2860
Q24236763-120392A3-E781-403E-AE6C-B5B3EA3832DCQ30227236-C85672AE-723B-4834-8B59-72694FDD7625Q30381808-308DCA9C-DA8E-439B-8818-80707D753F42Q30987069-F6D0BB56-AAA0-48F7-BBB1-20126BB9EDD1Q31043326-93D85B62-118D-4ED1-9EEF-3FD9850E556AQ33811136-AA6C8FF7-C3C9-4BBB-9903-8447BAE15ECCQ33830084-16EFD541-F693-4CAD-8266-50E77F19EE18Q33984272-420D7B84-F119-4702-B5DF-FA9BCEF78AABQ34181776-6CBC3221-7105-419A-A475-E4D65C799A6DQ34306176-31CE698F-ABF1-4DAB-9FBB-21AF4EEA4130Q34348392-82139313-9CA8-4854-9258-205939431978Q34395082-DE7863BE-2EEB-4AD3-B653-98F18A823D94Q34530379-4D75A064-8085-4441-8AF1-78A8AA96746FQ34632385-F0030E03-0FF1-4766-99F5-C269FB11EA32Q34981966-F45E7409-E0A4-4ED2-A6F7-FECDB7945927Q35037981-97050B65-3FC6-40A6-A6CE-51BA40BDB55AQ35184921-30CA447B-5DC3-48F7-9AB8-AB26C38FEA2CQ35551457-9C310523-F0C2-4215-A847-1CBE28F79269Q35557216-C1C94F93-D143-449D-8CCE-BABCF531A9BDQ35629349-250E80E0-7DD7-48C3-8CD2-CA06F771C295Q35691443-F2279CA2-5C15-40D4-9C7B-D3E4A9EBE80FQ35738557-21CAF0C9-AB74-4D04-968D-3158D7115D92Q35738687-54F18930-E251-4A36-AB64-13C0F7F95BD9Q36072127-7317832A-4D52-42FF-8772-D9443066B7B7Q36073787-ECA71B00-AB8E-45EE-82BC-7A9EB0EC5726Q36296422-684DF8CF-435E-49F6-98EA-6D896F909C2EQ36322136-FACC714E-6818-47BE-80E5-3A9A4059EB57Q36446890-FF00E10A-F8C1-4B7C-BB98-A61426182097Q36497045-8B13373D-CEE7-4F2A-98BC-BB98EF675A82Q36678190-3BCE3DC8-93A8-458D-902F-D2E04EE9385DQ36711601-15FD5FDA-F876-4B52-B501-CBD17C9171E8Q36851168-1D251565-7015-40BE-B825-D663E498A9B8Q37409196-4DB91085-8A86-4C1B-9ECE-5298C8743605Q37439907-AD971392-45D1-4D02-873F-7C8462CBB70DQ37608356-C40FBF7B-167D-4070-8BB1-FCA8A63D81A5Q37725144-E051D46D-6662-49AE-ACB0-1D70E18B9A44Q37870932-153B9062-D4BF-42B7-8B72-B619FF131C84Q38081072-0EDD8304-E793-4446-B91D-36213FD82B1BQ38185748-DB1F1359-EC8B-4EA8-B431-F9D3774AE1A4Q38366365-D29A3F1B-92AA-482B-B040-3402114B04AA
P2860
Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@en
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@nl
type
label
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@en
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@nl
prefLabel
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@en
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@nl
P2093
P1476
Improved obstetric outcomes an ...... iral therapy during pregnancy.
@en
P2093
Bruce Thompson
Carmen Zorrilla
D Heather Watts
Hunter Hammill
Mark Vajaranant
Ruth E Tuomala
Sheldon Landesman
Women and Infants Transmission Study
P304
P356
10.1097/01.QAI.0000139398.38236.4D
P407
P577
2005-04-01T00:00:00Z